ERCC1, MLH1, MSH2, MSH6, and βiII-tubulin: Resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma

Clinical Lung Cancer

Volumn 14, Issue 5, 2013, Pages

  Ting, Saskia ^a   Mairinger, Fabian D ^a   Hager, Thomas ^a   Welter, Stefan ^a   Eberhardt, Wilfried E ^a   Wohlschlaeger, Jeremias ^a   Schmid, Kurt W ^a   Christoph, Daniel C ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Biomarker; DNA repair; Immunohistochemistry; Pyrosequencing; Tailored therapy

Indexed keywords

BETA III TUBULIN; BETA TUBULIN; CARBOPLATIN; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CANCER TISSUE; CODON; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; FEMALE; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PYROSEQUENCING; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE;

BIOMARKER; DNA REPAIR; IMMUNOHISTOCHEMISTRY; PYROSEQUENCING; TAILORED THERAPY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; MUTS HOMOLOG 2 PROTEIN; NEOPLASM STAGING; NUCLEAR PROTEINS; PROGNOSIS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUBULIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84883788260     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2013.04.013     Document Type: Article

References (44)

1. S. Tomek, S. Emri, and K. Krejcy Chemotherapy for malignant pleural mesothelioma: past results and recent developments Br J Cancer 88 2003 167 174
2. T. Treasure, and A. Sedrakan Pleural mesothelioma: little evidence, still time to do trials Lancet 364 2004 1183 1185
3. A.S. Tsao, I. Wistuba, and J.A. Roth Malignant pleural mesothelioma J Clin Oncol 27 2009 2081 2090
4. J.E. Herndon, M.R. Green, and A.P. Chahinian Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B Chest 113 1998 723 731
5. G.L. Ceresoli, P.A. Zucali, and A.G. Favaretto Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma J Clin Oncol 24 2006 1443 1448
6. G.L. Ceresoli, B. Castagneto, and P.A. Zucali Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials Br J Cancer 99 2008 5155 5156
7. P.A. Zucali, E. Giovanetti, and A. Destro Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin Clin Cancer Res 17 2011 2581 2590
8. N.S. Kamal, J.-C. Soria, and J. Mendiboure MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer Clin Cancer Res 16 2010 1206 1215
9. R.J. Kelly, E. Sharon, and R. Hassan Chemotherapy and targeted therapies for unresectable malignant mesothelioma Lung Cancer 73 2011 256 263
10. S. Tomek, and C. Manegold Chemotherapy for malignant pleural mesothelioma: past results and recent developments Lung Cancer 45 2004 S103 S119
11. C. Camps, C. Sarries, and B. Roig Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine/cisplatin- treated advanced non-small-cell lung cancer patients Clin Lung Cancer 4 2003 237 241
12. K.A. Olaussen, G. Mountzios, and J.-C. Soria ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer Curr Opin Pul Med 13 2007 284 289
13. R. Rosell, M. Taron, and A. Barnadas Nucleotide excision repair pathways involved in cisplatin resistance in non-small-cell lung cancer Cancer Control 10 2003 297 305
14. R. Booton, T. Ward, and L. Ashcroft ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer J Thorac Oncol 2 2007 902 906
15. L. Friboulet, D. Barrios-Gonzales, and F. Commo Molecular characteristics of ERCC1-negative versus ERCC1-positive tumors in resected NSCLC Clin Cancer Res 17 2011 5562 5572
16. T. Fujii, S. Toyooka, and K. Ichimura ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer Lung Cancer 59 2008 377 384
17. R.A. Hubner, R.D. Riley, and L.J. Billingham Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations PLoS One 6 2011 e25164
18. Z.G. Zimling, J.B. Sorensen, and T.A. Gerds Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival J Thorac Oncol 7 2012 249 256
19. N.R. Bhagwat, V.Y. Roginskaya, and M.B. Acquafondata Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue Cancer Res 69 2009 6831 6838
20. K.M. Kerr Personalized medicine for lung cancer: new challenges for pathology Histopathology 60 2011 531 546
21. K.A. Olaussen, A. Dunant, and P. Fouret DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy N Engl J Med 355 2006 983 991
22. S.A. Martin, C.J. Lord, and A. Ashworth DNA repair deficiency as a therapeutic target in cancer Curr Opin Genet Div 18 2008 80 86
23. M. Cobo, D. Isla, and B. Massuti Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer J Clin Oncol 25 2007 2747 2754
24. S.A. Martin, A. McCarthy, and L.J. Barber Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2 EMBO Mol Med 1 2009 323 337
25. S.A. Martin, N. McCabe, and M. Mullarkey DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1 Cancer Cell 17 2010 235 248
26. Y.-L. Lo, C.-F. Hsiao, and Y.-S. Jou Polymorphisms of MLH1 and MSH2 genes and the risk of lung cancer among never smokers Lung Cancer 72 2010 280 286
27. D. Vageli, Z. Daniil, and J. Dahabreh Phenotypic mismatch repair hMSH2 and hMLH1 gene expression profiles in primary non-small cell lung carcinomas Lung Cancer 64 2009 282 288
28. M. Kim, H.-G. Kang, and S.Y. Lee Comprehensive analysis of DNA repair gene polymorphisms and survival in patients with early stage non-small-cell lung cancer Cancer Sci 101 2011 2436 2442
29. W. Zhou, S. Gurubhagavatula, and G. Liu Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy Clin Cancer Res 10 2004 4939 4943
30. D. Isla, C. Sarries, and R. Rosell Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer Ann Oncol 15 2004 1194 1203
31. K. Okuda, H. Sasaki, and Y. Hikosaka Excision repair cross complementation group 1 polymorphisms predict overall survival after platinum-based chemotherapy for completely resected non-small-cell lung cancer J Surg Res 168 2011 206 212
32. M. Mariani, S. Shahabi, and S. Sieber Class III ß-tubulin (TUBB3): more than a biomarker in solid tumors? Curr Mol Med 11 2011 726 731
33. P.P. Gan, E. Pasquier, and M. Kavallaris Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer Cancer Res 67 2007 9356 9363
34. J.A. McCarroll, P.P. Gan, and M. Liu betaIII-tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer Cancer Res 70 2010 4995 5003
35. L. Righi, M.G. Papotti, and P. Ceppi Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy J Clin Oncol 28 2010 1534 1539
36. V.W. Rusch A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group Chest 108 1995 1122 1128
37. M.J. Byrne, and A.K. Nowak Modified RECIST criteria for assessment of response in malignant pleural mesothelioma Ann Oncol 15 2005 257 260
38. G.L. Ceresoli, A. Chiti, and P.A. Zucali Assessment of tumor response in malignant pleural mesothelioma Cancer Treat Rev 33 2007 533 541
39. D.C. Christoph, B. Reyna-Asuncion, and C. Mascaux Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma J Thorac Oncol 7 2012 1440 1448
40. C. Chao, Y.-M. Zhang, and R. Wang Excision repair cross complementation group 1 polymorphisms and lung cancer risk: a meta-analysis Chin Med J (Engl) 124 2011 2203 2208
41. T. Reiman, R. Lai, and A.S. Veillard Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials Ann Oncol 23 2011 86 93
42. L.J. Niedernhofer, N. Bhagwat, and R.D. Wood ERCC1 and non-small-cell lung cancer N Engl J Med 356 2007 2538 2539
43. K.A. Olaussen, P. Fouret, and G. Kroemer ERCC1-specific immunostaining in non-small-cell lung cancer N Engl J Med 357 2007 1559 1561
44. L. Friboulet, K.E. Olaussen, and J.-P. Pignon ERCC1 isoform expression and DNA repair in non-small-cell lung cancer N Engl J Med 368 2013 1101 1110